Download fulltext
HTML
1.
Tadayoni R. Time to Call into Question the Fundus-based Evaluation of Diabetic Retinopathy after Intravitreal Injections. JOVR [Internet]. 2020Feb.3 [cited 2024Apr.25];15(1):4–6. Available from: https://knepublishing.com/index.php/JOVR/article/view/5971
https://doi.org/10.18502/jovr.v15i1.5971
statistics
- 560 Abstract Views
- 322 PDF Views
- 0 HTML Views
- Cited by 1 article
authors
-
Ramin Tadayoni
Ramin Tadayoni
Department of Ophthalmology, Hôpital Lariboisière, AP-HP, Université de Paris, Paris, France
Published Date
- Feb 3, 2020
Time to Call into Question the Fundus-based Evaluation of Diabetic Retinopathy after Intravitreal Injections
Abstract
This is an Editorial and does not have an abstract.
Keywords:
NA
References
1. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991;98:823–833.
2. Fluorescein angiographic risk factors for progression of diabetic retinopathy. ETDRS report number 13. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991;98:834–840.
3. Ip MS, Domalpally A, Sun JK, Ehrlich JS. Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy. Ophthalmology 2015;122:367–374.
4. Writing committee for the Diabetic Retinopathy Clinical Research Network, Gross JG, Glassman AR, Jampol LM, Inusah S, Aiello LP, et al. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA 2015;314:2137–2146.
5. Wubben TJ, Johnson MW; Anti-VEGF Treatment Interruption Study Group. Anti-VEGF therapy for diabetic retinopathy: consequences of inadvertent treatment interruptions. Am J Ophthalmol 2019;204:13–18.
6. Bonnin S, Dupas B, Lavia C, Erginay A, Dhundass M, Couturier A, et al. Anti-vascular endothelial growth factor therapy can improve diabetic retinopathy score without change in retinal perfusion. Retina 2019;39:426–434.
7. Couturier A, Rey PA, Erginay A, Lavia C, Bonnin S, Dupas B, et al. Swept-source wide-field OCT-angiography versus ultra-wide-field fluorescein angiography assessments of retinal non-perfusion in diabetic retinopathy and edema treated with anti-VEGF. Accepted for publication in Ophthalmology 2019.
2. Fluorescein angiographic risk factors for progression of diabetic retinopathy. ETDRS report number 13. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991;98:834–840.
3. Ip MS, Domalpally A, Sun JK, Ehrlich JS. Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy. Ophthalmology 2015;122:367–374.
4. Writing committee for the Diabetic Retinopathy Clinical Research Network, Gross JG, Glassman AR, Jampol LM, Inusah S, Aiello LP, et al. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA 2015;314:2137–2146.
5. Wubben TJ, Johnson MW; Anti-VEGF Treatment Interruption Study Group. Anti-VEGF therapy for diabetic retinopathy: consequences of inadvertent treatment interruptions. Am J Ophthalmol 2019;204:13–18.
6. Bonnin S, Dupas B, Lavia C, Erginay A, Dhundass M, Couturier A, et al. Anti-vascular endothelial growth factor therapy can improve diabetic retinopathy score without change in retinal perfusion. Retina 2019;39:426–434.
7. Couturier A, Rey PA, Erginay A, Lavia C, Bonnin S, Dupas B, et al. Swept-source wide-field OCT-angiography versus ultra-wide-field fluorescein angiography assessments of retinal non-perfusion in diabetic retinopathy and edema treated with anti-VEGF. Accepted for publication in Ophthalmology 2019.